PMID- 37945142
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20240201
IS  - 1558-5042 (Electronic)
IS  - 1055-3207 (Linking)
VI  - 33
IP  - 1
DP  - 2024 Jan
TI  - Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma.
PG  - 173-195
LID - S1055-3207(23)00063-7 [pii]
LID - 10.1016/j.soc.2023.06.012 [doi]
AB  - Hepatocellular carcinoma (HCC)is a common type of liver cancer with a poor 
      prognosis, especially in patients with advanced stages or underlying liver 
      disease. While surgical resection, liver transplantation, and ablation therapies 
      have traditionally been the mainstay of treatment for HCC, radiation therapy has 
      become increasingly recognized as an effective alternative, particularly for 
      those who are not surgical candidates. Stereotactic Body Radiation Therapy (SBRT) 
      is a highly precise form of radiation therapy that delivers very high doses of 
      radiation to the tumor while sparing surrounding healthy tissue. Several studies 
      have reported favorable outcomes with SBRT in HCC treatment. Moreover, SBRT can 
      be used to treat recurrent HCC after prior treatment, offering a potentially 
      curative approach in select cases. While SBRT has demonstrated its efficacy and 
      safety in treating HCC, future studies are needed to further investigate the 
      potential role of SBRT in combination with other treatments for HCC.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Abualnil, Aseel Y
AU  - Abualnil AY
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, 
      USA.
FAU - Kumar, Ritesh
AU  - Kumar R
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, 
      USA.
FAU - George, Mridula A
AU  - George MA
AD  - Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, 
      USA.
FAU - Lalos, Alexander
AU  - Lalos A
AD  - Division of Gasteroenterology and Hepatology, Rutgers Robert Wood Johnson Medical 
      School, Rutgers University, New Brunswick, NJ 08901, USA.
FAU - Shah, Mihir M
AU  - Shah MM
AD  - Division of Surgical Oncology, Department of Surgery, Emory University School of 
      Medicine, Atlanta, GA 30342, USA.
FAU - Deek, Matthew P
AU  - Deek MP
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, 
      USA.
FAU - Jabbour, Salma K
AU  - Jabbour SK
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers 
      Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, 
      USA. Electronic address: jabbousk@cinj.rutgers.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230825
PL  - United States
TA  - Surg Oncol Clin N Am
JT  - Surgical oncology clinics of North America
JID - 9211789
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Liver Neoplasms/pathology
MH  - *Radiosurgery
MH  - Treatment Outcome
MH  - Combined Modality Therapy
OTO - NOTNLM
OT  - Bridge-therapy
OT  - Hepatocellular carcinoma (HCC)
OT  - Radiation therapy
OT  - Stereotactic body radiation therapy (SBRT)
OT  - Transarterial chemoembolization
EDAT- 2023/11/10 00:44
MHDA- 2023/11/13 06:41
CRDT- 2023/11/09 20:57
PHST- 2023/11/13 06:41 [medline]
PHST- 2023/11/10 00:44 [pubmed]
PHST- 2023/11/09 20:57 [entrez]
AID - S1055-3207(23)00063-7 [pii]
AID - 10.1016/j.soc.2023.06.012 [doi]
PST - ppublish
SO  - Surg Oncol Clin N Am. 2024 Jan;33(1):173-195. doi: 10.1016/j.soc.2023.06.012. 
      Epub 2023 Aug 25.